

that are eligible for the funding priorities are awarded additional points towards their final rank order score. The largest number of funding priority points is proposed for applications that are most likely to have a demonstrable impact on consent rates. Five (5) points will be awarded for this funding priority. Funding priority is also proposed for projects that address variations in consent by race and ethnicity, which may include an examination of differences in donation/transplantation knowledge, attitudes, and experiences among one or more minority groups. Two (2) points will be awarded for this funding priority. For applications that qualify, Government program staff will add the appropriate points to the score assigned by the peer review panel. (Maximum total points any application can achieve for all review criteria will be 107.)

HRSA reserves the option to fund a balance of projects in Phases 1 and 2.

#### **Project Period**

Projects will be awarded for up to 3 years.

#### **Estimated Amount Available For This Competition**

HRSA expects to award under this program up to \$5 million in FY99 to support the first year of approximately 15–20 projects. Subsequent years' funding depends on the availability of appropriations, program priorities, and recipient performance.

Dated: March 30, 1999.

**Claude Earl Fox,**

*Administrator.*

[FR Doc. 99–8175 Filed 4–2–99; 8:45 am]

BILLING CODE 4160–15–P

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Health Resources and Services Administration**

#### **National Advisory Council on Migrant Health; Notice of Meeting**

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice of Meeting.

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), announcement is made of the following National Advisory body scheduled to meet during the month of April 1999:

*Name:* National Advisory Council on Migrant Health.

*Date & Time:* Wednesday, April 21, 1999 at 9:00 A.M. to Thursday, April 22, 1999 at 5:00 P.M..

*Place:* Denver Marriott Center City, 1701 California Street, Denver, CO 80202, 303/297–1300 phone, 303/298–7474 fax. The meeting is open to the public.

*Agenda:* This will be a meeting of the Council. The agenda includes an overview of general Council business activities and priorities. Topics of discussion will include the State Children's Health Insurance Program, Migrant issues in Colorado, and updates from programs funded by the Migrant Health Program. The Council meeting is being held in conjunction with the National Association of Community Health Centers (NACHC), 1999 National Farmworker Health Conference, April 23–25, 1999. Anyone requiring information regarding the subject Council should contact Susan Hagler, Migrant Health Program, staff support to the National Advisory Council on Migrant Health, Bureau of Primary Health Care, Health Resources and Services Administration, 4350 East West-Highway, Bethesda, Maryland 20814, Telephone 301/594–4302.

Agenda Items are subject to change as priorities indicate.

Dated: March 30, 1999.

**Jane M. Harrison,**

*Director, Division of Policy Review and Coordination.*

[FR Doc. 99–8198 Filed 4–2–99; 8:45 am]

BILLING CODE 4160–15–P

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Cancer Cell Biology, Tumor Biology and Genetic Conference Grants.

*Date:* April 8, 1999.

*Time:* 1:00 PM to 3:00 PM.

*Agenda:* To review and evaluate grant applications.

*Place:* 6130 Executive Boulevard, EPN, Room 635, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Olivia T. Preble, PHD, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard—Rm. 643B, Rockville, MD 20892–7405, 301/496–7929.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction, 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower, 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 30, 1999.

**Anna Snouffer,**

*Acting Committee Management Officer, NIH.*

[FR Doc. 99–8320 Filed 4–2–99; 8:45 am]

BILLING CODE 4140–01–M

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Preclinical Evaluation of Intermediate Endpoints and their Modulation by Chemopreventive Agents.

*Date:* April 6, 1999.

*Time:* 1:00 PM to 3:00 PM.

*Agenda:* To review and evaluate contract proposals.

*Place:* 6130 Executive Blvd. 6th Floor, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Wilna A. Woods, PHD, Deputy Chief, Special Review, Referral and Research Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, (301) 496–7903.